In summary, our findings support that, pending further clinical validation, immunohistochemical assessment of RelB expression at the time of diagnosis of laryngeal cancer is intimately linked with tumor progression and can accurately predict prognosis. The gene discussed is RELB; the disease is laryngeal carcinoma.